The Japanese Ministry of Health, Labour and Welfare has approved Fasenra (benralizumab), from AstraZeneca (LON: AZN) and its global biologics research and development arm, MedImmune, the company disclosed on Friday.
The drug has been approved as an add-on treatment for bronchial asthma in patients who continue to experience asthma exacerbations despite receiving treatment with high-dose inhaled corticosteroid and other asthma controllers.
The decision was based on results from the WINDWARD programme, which included the pivotal Phase III exacerbation trials, SIROCCO and CALIMA, as well as the Phase III oral corticosteroid (OCS)-sparing trial, ZONDA.
Fasenra will now be available to eligible patients in Japan as a fixed-dose subcutaneous injection in a pre-filled syringe administered once every four weeks for the initial three doses, and then once every eight weeks thereafter.
The approval in Japan follows approval from the US Food and Drug Administration (FDA) in November and marketing authorisation from the European Commission in January 2018. The company is continuing interactions with regulatory authorities in the rest of the world.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial